Waters Corporation
NYSE•WAT
CEO: Dr. Udit Batra Ph.D.
板块: Healthcare
行业: Medical - Diagnostics & Research
上市日期: 1995-11-17
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
联系方式
市值
$18.99B
市盈率 (TTM)
29.6
31.5
股息率
--
52周最高
$414.15
52周最低
$275.05
52周范围
排名27Top 14.4%
5.4
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
一般 • 5.4 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q4 2025 数据
营业收入
$932.36M+0.00%
近4季度走势
每股收益
$3.78+0.00%
近4季度走势
自由现金流
$125.58M+0.00%
近4季度走势
2025 Annual 财报亮点
核心亮点
Total Net Sales Increase Total net sales reached $3.17B USD in 2025, marking a 7% increase driven by strong customer demand across major geographies.
Chemistry Consumables Growth Chemistry consumables sales grew 12% to $631.5M USD in 2025, supported by uptake in columns and pharmaceutical testing kits.
Transformative BDS Acquisition Completed $16.8B USD acquisition of BD Biosciences & Diagnostic Solutions in February 2026, establishing a global life sciences leader.
Net Income Remained Stable Net income was $642.6M USD in 2025, showing a 1% increase despite operating income declining 3% from prior year.
关注风险
BDS Integration Challenges Failure to integrate BDS Business within expected timeline could adversely affect future results and realization of anticipated synergies.
Foreign Currency Fluctuation Risk International operations face negative impact from foreign currency fluctuations, affecting translation of non-U.S. operating results.
Customer Demand Changes Financial results subject to changes in customer demand, especially pharmaceutical spending, which may decrease beyond Company control.
Competitive Technology Disruption Competitors may introduce more effective or less expensive products, potentially decreasing sales and harming market position.
前瞻展望
Increased R&D Investment R&D expenses increased 7% in 2025 to $195.7M USD, reflecting commitment to new product development and technology initiatives.
New Four Segment Structure Reorganized business into four segments post-BDS acquisition: Analytical, Biosciences, Advanced Diagnostics, and Materials Sciences.
Realizing Acquisition Synergies Expect cost synergies of $200M USD within three years and revenue synergies of $290M USD within five years post-BDS close.
Share Repurchase Authorization Board authorized share repurchase extension through January 2028, maintaining $1.0B remaining authorization capacity.
同行对比
营业收入 (TTM)
$13.95B
$11.04B
$9.81B
毛利率 (最新季度)
92.3%
90.9%
86.9%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| DXCM | $28.43B | 33.7 | 32.4% | 21.9% |
| BIIB | $27.88B | 21.5 | 7.3% | 23.6% |
| MTD | $26.28B | 30.2 | -487.2% | 63.1% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
12.1%
稳定增长
4季度净利润复合增长率
22.9%
盈利能力强劲提升
现金流稳定性
100%
现金流表现优异
深度研究
下次财报:2026年5月4日
每股收益:-
|营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据